Alpine Immune Sciences, Inc. (NASDAQ:ALPN) headquartered in Seattle, will host a conference call for the investment community to discuss the 2Q20 financial results on 11th August 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.alpineimmunesciences.com
Earnings Expectation
Alpine Immune Sciences, Inc. is expected to report second quarter earnings results, after market close, on Tuesday 11th August 2020. Analysts polled by Thomson Reuters anticipate second quarter income of $ 0.53 per share. Looking ahead, the full year loss are expected at $ 0.04 per share on the revenues of $ 27.99 million.
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
